Stemline Therapeutics (NASDAQ:STML) Upgraded by Wedbush to Outperform

Stemline Therapeutics (NASDAQ:STML) was upgraded by analysts at Wedbush from a “neutral” rating to an “outperform” rating in a report issued on Friday, The Fly reports.

Other analysts have also issued reports about the stock. Roth Capital restated a “buy” rating on shares of Stemline Therapeutics in a research note on Thursday, May 23rd. Zacks Investment Research raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Saturday, July 27th. HC Wainwright set a $35.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 20th. ValuEngine lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th. Finally, BidaskClub lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 4th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $23.50.

Shares of Stemline Therapeutics stock traded up $2.45 during trading on Friday, hitting $15.48. The company’s stock had a trading volume of 38,931 shares, compared to its average volume of 301,442. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.07 and a quick ratio of 5.03. The business’s fifty day moving average price is $14.16. The firm has a market capitalization of $598.92 million, a P/E ratio of -5.18 and a beta of 1.33. Stemline Therapeutics has a 52 week low of $7.82 and a 52 week high of $17.85.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.06). The business had revenue of $5.05 million for the quarter, compared to analyst estimates of $2.61 million. As a group, equities research analysts anticipate that Stemline Therapeutics will post -2.09 EPS for the current fiscal year.

In related news, CEO Ivan Bergstein sold 10,822 shares of Stemline Therapeutics stock in a transaction on Monday, June 24th. The stock was sold at an average price of $15.49, for a total value of $167,632.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Kenneth Hoberman sold 9,107 shares of Stemline Therapeutics stock in a transaction on Monday, June 24th. The stock was sold at an average price of $15.49, for a total value of $141,067.43. The disclosure for this sale can be found here. In the last ninety days, insiders sold 149,177 shares of company stock valued at $2,236,377. 13.10% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in STML. BlackRock Inc. grew its position in Stemline Therapeutics by 4.9% during the fourth quarter. BlackRock Inc. now owns 2,065,239 shares of the biopharmaceutical company’s stock valued at $19,618,000 after buying an additional 95,747 shares during the period. Bank of New York Mellon Corp grew its holdings in Stemline Therapeutics by 26.5% during the fourth quarter. Bank of New York Mellon Corp now owns 134,756 shares of the biopharmaceutical company’s stock valued at $1,281,000 after purchasing an additional 28,198 shares during the period. Great West Life Assurance Co. Can bought a new stake in Stemline Therapeutics during the fourth quarter valued at about $47,000. Dimensional Fund Advisors LP grew its holdings in Stemline Therapeutics by 8.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 185,395 shares of the biopharmaceutical company’s stock valued at $1,761,000 after purchasing an additional 14,275 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Stemline Therapeutics by 10.8% during the fourth quarter. Geode Capital Management LLC now owns 311,327 shares of the biopharmaceutical company’s stock valued at $2,956,000 after purchasing an additional 30,324 shares during the period. Institutional investors and hedge funds own 78.79% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: Penny Stocks, What You Need To Know

The Fly

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.